NIMOTOP 0.2 mg/ml SOLUTION FOR INFUSION

2. What you need to know before you use Nimotop

Do not use Nimotop

• if you are allergic (hypersensitive) to nimodipine or any of the other ingredients of this medicine (listed in section 6).
• if you have severe liver disease (e.g., cirrhosis).

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to use Nimotop.

• if you have blood pressure disorders or are being treated to lower your blood pressure, especially in patients with systolic blood pressure below 100 mmHg.
• if you have cerebral edema (generalized brain swelling) or if there is marked intracranial hypertension, although treatment with nimodipine has not been associated with increases in intracranial pressure.
• if you have kidney disease.
• if you have suffered a cerebral trauma that has caused an intracranial hemorrhage.
• if you have unstable angina (a disease in which the heart does not receive enough blood flow and oxygen and can lead to a heart attack) or if you have had an acute myocardial infarction four weeks ago, in these circumstances your doctor will assess the possible benefit versus the risk.
• if you have heart problems such as cardiac arrhythmias and heart failure (a disease in which the heart is unable to pump enough blood to meet the body's needs), in these circumstances your doctor will perform periodic checks.

Using Nimotop with other medicines

Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines, including those obtained without a prescription.

Certain medicines may interact with nimodipine; in these cases, your doctor will adjust the dose or interrupt treatment with one of the medicines. This is especially important when taking:

• Cimetidine (a medicine used to treat stomach ulcers) or valproic acid (used to treat epilepsy), as they may potentiate the hypotensive effect of nimodipine.
• Antihypertensive medicines (used to treat high blood pressure), as they may potentiate the hypotensive effect of nimodipine.
• Antiretroviral medicines (used to treat HIV infection) such as zidovudine.
• Other calcium antagonists (e.g., nifedipine, diltiazem, or verapamil) or with alpha-methyldopa. However, if it is essential to administer this combination, the patient's blood pressure will be monitored, especially.

• Potentially nephrotoxic medicines (those that damage the kidneys, e.g., aminoglycosides, cephalosporins, furosemide), kidney function may deteriorate. In these cases, kidney function will be carefully monitored, and if deterioration is observed, treatment will be considered for suspension.

• The simultaneous intravenous administration of beta-blockers (used to treat hypertension and heart problems, e.g., atenolol, propranolol, carvedilol) may cause an additional decrease in blood pressure and a mutual potentiation of the negative inotropic effect, which could lead to decompensation of pre-existing heart failure.
• Medicines incompatible with alcohol, since this medicine contains a volume percentage of alcohol of 23.7%, i.e., up to 50 g per daily dose (250 ml).
• The antidepressants fluoxetine and nortriptyline.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Nimotop is contraindicated during pregnancy and breastfeeding, unless prescribed by a doctor.

If it is necessary to administer nimodipine during pregnancy, your doctor will carefully assess the potential benefits and risks based on the severity of the clinical condition.

Driving and using machines

It is unlikely that you will be able to perform these activities while receiving nimodipine infusion.

Nimotop contains alcohol

This medicine contains 23.7% ethanol (alcohol); this corresponds to an amount of 1.89 g per hour of infusion, equivalent to 50 ml of beer or 20 ml of wine. It is unlikely that the amount of alcohol in this medicine will have any noticeable effect in adults or adolescents. It may have some effects in small children, such as drowsiness.

The alcohol content should be taken into account in the case of pregnant or breastfeeding women, children, and high-risk groups, such as patients with liver disease or epilepsy. The amount of alcohol in this medicine may alter the effects of other medicines. Consult your doctor or pharmacist if you are taking other medicines. Since this medicine is administered slowly through continuous infusion, the effects of alcohol may be reduced.

If you have an alcohol addiction, consult your doctor or pharmacist before taking this medicine.

Nimotop contains sodium

This medicine contains 23.46 mg of sodium (the main component of table salt) per 50 ml vial. This is equivalent to 1.17% of the maximum recommended daily intake of sodium for an adult.

3. How to use Nimotop

Nimotop is a hospital medicine, so it will be administered to you in a hospital by the corresponding healthcare personnel.

Follow exactly the administration instructions of this medicine indicated by your doctor, pharmacist, or nurse. If in doubt, ask your doctor, pharmacist, or nurse.

The usual treatment period is to administer the infusion solution for 5-14 days, followed by administration of 2 tablets of 30 mg, 6 times a day (6 x 60 mg of nimodipine) for approximately 7 more days.

Use in children and adolescents

The use of nimodipine is not recommended in children under 18 years of age, as its safety and efficacy have not been established.

If you have been given too much Nimotop

The symptoms you may experience are: marked decrease in blood pressure, increase or decrease in heart rate.

In case of overdose or accidental ingestion, consult your doctor, pharmacist, or nurse immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.

If you missed using Nimotop

Since this medicine is for hospital use due to its indications, this information does not apply.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been described with the following frequencies:

Common: may affect up to 1 in 10 people

Uncommon: may affect up to 1 in 100 people

Rare: may affect up to 1 in 1,000 people

Very rare: may affect up to 1 in 10,000 people

Not known: frequency cannot be estimated from the available data

Blood and lymphatic system disorders

• Thrombocytopenia (decrease in platelet count) is uncommon.

Immune system disorders

• Acute hypersensitivity reactions include mild or moderate allergic reactions, which are uncommon.
• Clinical symptoms associated with them are related to the skin (uncommon rash).

Nervous system disorders

• Unspecific cerebrovascular symptoms include uncommon headaches.

Cardiac disorders

• Changes in heart rate (unspecific cardiac arrhythmias): tachycardia (increased heart rate) is uncommon and bradycardia (decreased heart rate) is rare.

Vascular disorders

• Unspecific cardiovascular symptoms, such as hypotension (decrease in blood pressure) and vasodilation, are uncommon.

Respiratory, thoracic, and mediastinal disorders

• Low oxygen levels in body tissues, frequency not known.

Gastrointestinal disorders

• Unspecific gastrointestinal and abdominal symptoms include uncommon nausea.
• Rarely, ileus (intestinal obstruction) has been reported.

Hepatobiliary disorders

• Hepatic reactions consist of a transient and rare increase in liver enzymes (including increased transaminases, alkaline phosphatase, and γ-GT).

General disorders and administration site conditions

• Reactions at the infusion site and injection site are rare (including thrombophlebitis at the infusion site, when a clot forms in a vein).

If you experience side effects, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet.

Reporting of side effects:

If you experience any side effects, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Nimotop

Keep this medicine out of the sight and reach of children.

Store in the original package.

Protect from direct sunlight, if the vial is removed from its packaging.

Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

Composition of Nimotop

• The active substance is nimodipine. Each ml of the solution contains 0.2 mg.
• The other ingredients are ethanol 96%, macrogol 400, sodium citrate, citric acid, and water for injections.

Appearance of the product and pack contents

Nimotop is presented in a vial in the form of a slightly yellowish solution. Each pack contains 20 vials of 50 ml (Clinical Pack).

Marketing authorization holder and manufacturer

The marketing authorization holder is:

Laboratoire X.O

170 Bureaux de la Colline

92213 Saint-Cloud Cedex

France

The manufacturer is:

Bayer AG

Kaiser-Wilhelm-Allee

51368 Leverkusen

Germany

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Beatriz López Pascual

C/ Las artes, 13, 5°D,

33402-Avilés (Asturias)

Spain

Phone: +34 626 028 201

Email: [email protected]

Date of last revision of this leaflet:September 2024

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

-------------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals.

NIMOTOP0.2 mg/ml, solution for infusion

Instructions for use and handling

The medicine should be administered by continuous intravenous infusion through a central catheter connected to an infusion pump using a 3-way valve along with a 5% glucose solution, 0.9% sodium chloride solution, Ringer's lactate, Ringer's lactate with magnesium, dextran 40, or 6% hydroxyethyl starch solution in a ratio of approximately 1:4 (Nimotop: co-infusion). Mannitol, albumin, or human blood are also suitable for simultaneous infusion.

Nimotop solution should not be added to an infusion bag or bottle and should not be mixed with other medicines. The solution should be withdrawn from the vial using a syringe (do not withdraw directly with an infusion pump). Then, place the syringe without a needle in a syringe infusion pump and connect it to the 3-way valve using the polyethylene tube supplied in the package (do not use standard PVC tubes). In turn, connect the co-infusion tube and the central catheter to the 3-way valve. Nimotop administration will continue during anesthesia, surgery, and cerebral angiography.

In patients in whom the administration of an additional volume of fluids is not recommended or may be contraindicated, the preparation can be used directly through a central catheter without using a co-infusion.

Intracisternal instillation:

During surgery, a freshly prepared diluted solution of Nimotop (1 ml of Nimotop solution and 19 ml of Ringer's solution) warmed to blood temperature can be instilled into the cisterns. This diluted Nimotop solution should be used immediately after preparation.

Posology

As a general rule, the treatment regimen starts with the intravenous administration of nimodipine followed by oral administration, as specified below:

Treatment is initiated with the continuous intravenous infusion of 1 mg/h of nimodipine (= 5 ml nimodipine solution/h for 2 h (approximately 15 µg/kg/h). If well tolerated, and no marked decreases in blood pressure are observed, after 2 h the dose is increased to 2 mg/h of nimodipine (= 10 ml nimodipine solution/h) (approximately 30 µg/kg/h). In patients with a body weight below 70 kg or unstable blood pressure, treatment should be started with a dose of 0.5 mg/h of nimodipine (= 2.5 ml of nimodipine solution/h), or less if considered necessary.